deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 5-arm NCT03225833

Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease (PRECISION-HD1)

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients With Huntington's Disease

Sponsor: Wave Life Sciences Ltd.

Conditions Huntington's Disease
Interventions Placebo WVE-120101
Updated 16 times since 2017 Last updated: Feb 9, 2022 Started: Jul 17, 2017 Primary completion: May 11, 2021 Completion: May 11, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Lack of Efficacy

Other terminated trials from Wave Life Sciences Ltd.

More terminations from Wave Life Sciences Ltd.

Other Huntington's Disease trials with similar outcome

Browse all Huntington's Disease trials

Listed as NCT03225833, this PHASE1/PHASE2 trial focuses on Huntington's Disease and remains terminated or withdrawn. Sponsored by Wave Life Sciences Ltd., it has been updated 16 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Aug 2017 – ~Nov 2017 · 3 months · monthly snapshot~Nov 2017 – ~Apr 2018 · 5 months · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Dec 2018 · 6 months · monthly snapshot~Dec 2018 – ~Jun 2019 · 6 months · monthly snapshot~Jun 2019 – ~Aug 2019 · 2 months · monthly snapshot~Aug 2019 – ~Apr 2020 · 8 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~May 2021 · 2 months · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Mar 2022 · 6 months · monthly snapshot~Mar 2022 – ~Jul 2024 · 28 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Mar 2022 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

  5. Sep 2021 — Mar 2022 [monthly]

    Terminated PHASE1_PHASE2

    Status: Active Not Recruiting → Terminated

▶ Show 11 earlier versions

  1. May 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  2. Mar 2021 — May 2021 [monthly]

    Recruiting PHASE1_PHASE2

  3. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE1_PHASE2

  4. Apr 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  5. Aug 2019 — Apr 2020 [monthly]

    Recruiting PHASE1_PHASE2

  6. Jun 2019 — Aug 2019 [monthly]

    Recruiting PHASE1_PHASE2

  7. Dec 2018 — Jun 2019 [monthly]

    Recruiting PHASE1_PHASE2

  8. Jun 2018 — Dec 2018 [monthly]

    Recruiting PHASE1_PHASE2

  9. Apr 2018 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  10. Nov 2017 — Apr 2018 [monthly]

    Recruiting PHASE1_PHASE2

  11. Aug 2017 — Nov 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Jul 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Wave Life Sciences Ltd.
Data source: Wave Life Sciences Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aarhus, Denmark , Carlton, Australia , Clayton, Australia , Copenhagen, Denmark , Créteil, France , Edmonton, Canada , Exeter, United Kingdom , Gdansk, Poland , Glasgow, United Kingdom , Herston, Australia and 11 more locations